Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by Lynx9on Jul 16, 2018 3:07pm
92 Views
Post# 28322838

RE:Alternate research

RE:Alternate researchOne of the conundrums of being a puplic co on the leading edge of med tecnology is that you have to release small bits of information in order to satisfy both invetors and shareholders. By doing this, you release small tidbits of relevent information that other, just as intelligent individuals and corporations, may use or clue in to on there own research. There is huge competition to find a cure or atleast a deterrent to this demeaning disease. The race is on and news will not be forthcoming because of it. This is a long term "turkey shoot" and highly speculative business. Not for the skimish or quick $hit investors. In saying that don't marry the stock and take some money out as it presents itself, if your not doing it you can best assured insiders and big money investors are!
Bullboard Posts